Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial-Reference-Cited by-同舟云学术

Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial

Published:2022-06 Issue: Volume:168 Page:91-98
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Freemantle Nick,Mollon Patrick,Meyer Tim,Cheng Ann-Lii,El-Khoueiry Anthony B.,Kelley Robin K.,Baron Ari D.,Benzaghou Fawzi,Mangeshkar Milan,Abou-Alfa Ghassan K.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. Chemotherapy for hepatocellular carcinoma: the present and the future;Le Grazie;World J Hepatol,2017

2. Review article: systemic treatment of hepatocellular carcinoma;Pinter;Aliment Pharmacol Ther,2018

3. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N Engl J Med,2018

4. Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma;Zhou;Cancers,2019

5. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population;Steel;Qual Life Res : an international journal of quality of life aspects of treatment, care and rehabilitation,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy;World Journal of Oncology;2024-06

2. A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394;Liver Cancer;2024

3. Soghin clinical practice guidelines for hepatocellular carcinoma;Nigerian Journal of Gastroenterology and Hepatology;2023-01

4. Cabozantinib: A narrative drug review;Cancer Research, Statistics, and Treatment;2023

5. Hepatocellular carcinoma;The Lancet;2022-10